I believe the roll out of the Reata drug is a lot slower than DAYBUE which is very comforting…
Because of a manufacturing hitch, there was a delay in the US Skyclarys launch until late June last year, two months after DayBue’s launch.
Since then, Skyclarys has received approval in the EU (February 2024) and has already been filed for approval in Australia (May 2024). Q1 2024 sales were US$78m, slightly beating DayBue sales for the quarter of US$75.9m.
Share Price, page-10947
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.56 |
Change
-0.400(2.67%) |
Mkt cap ! $1.860B | |||
| Open | High | Low | Value | Volume |
| $14.96 | $15.00 | $14.18 | $7.303M | 503.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 30783 | $14.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.60 | 1006 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |